Anticonvulsants. 1. Alkoxymethyl Derivatives of Barbiturates and Diphenylhydantoin

CARLOS M. SAMOUR,¹ JOHN F. REINHARD,² AND JULIUS A. VIDA^{*1}

Kendall Company, T. Clark Laboratory, Cambridge, Massachusetts 02142, and the Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts 02115

Received August 6, 1970

Alkoxymethyl derivatives of barbiturates and 5,5-diphenylhydantoin are effective anticonvulsants. Particularly effective are 1,3-bis(alkoxymethyl)-5-ethyl-5-phenylbarbituric acids which possess marked anticonvulsant activity against both electrically and chemically induced seizures. 3-Alkoxymethyl-5,5-diphenylhydantoins were also active against both maximal electroshock and pentylenetetrazole-induced seizures.

Phenobarbital and diphenylhydantoin are the most widely used drugs in the treatment of epilepsies.³ However, phenobarbital has the disadvantage of being hypnotic, and occasionally produces a paradoxical exciting effect both in children and in the elderly.⁴ Diphenylhydantoin, on the other hand, is known to have a multiplicity of side effects, including hypertrophic gingivitis, hirsutism, toxic psychoses, and megaloblastic anemia.⁵


Our findings reveal that alkoxymethyl derivatives of barbiturates and diphenylhydantoin are effective anticonvulsants which possess potential advantages over their respective parent compounds.

The 1,3-bis(alkoxymethyl)phenobarbitals had marked anticonvulsant activity, yet were devoid of the hypnotic effects associated with the parent compound. Similarly the 1.3-bis(alkoxymethyl)barbitals had good activity against a convulsive dose of pentylenetetrazole, yet were devoid of hypnotic activity. In the 5,5-diphenylhydantoin series the 3-methoxymethyl derivative had the potency of the parent compound against maximal electroshock seizures and, unlike 5,5-diphenylhydantoin, was weakly active against pentylenetrazole. Even more surprising was the finding that 3-benzyloxymethyl-5,5-diphenylhydantoin, and 3-butoxymethyl-5,5-diphenylhydantoin, like 5,5-diphenylhydantoin, displayed good activity against maximal electroshock seizures but, unlike 5.5-diphenylhydantoin, were effective against chemoshock as well.

The 1,3-bis(alkoxymethyl) barbiturates may be prepared conveniently by treating a barbiturate salt with an alkyl halomethyl ether. Thus the reaction of equimolar amounts of Na phenobarbital (1) and ClCH₂-OCH₃ provided 1,3-bis(methoxymethyl)phenobarbital (2) in 50% yield. Fifty per cent of unreacted phenobarbital was recovered. The use of excess ClCH₂OCH₃ did not improve the yield of 2. This may be explained by the sequence of reactions shown in Scheme I.

1-Methoxymethylphenobarbital, the first product of the reaction sequence is transformed into its Na salt through equilification with the excess of 1. In turn,

(2) Northeastern University, Boston, Mass.



sodium 1-methoxymethylphenobarbital reacts with $ClCH_2OCH_3$ to produce 2. The recovery of 50% phenobarbital is also accounted for in the reaction sequence.

The dissociation constants of 5,5-disubstituted barbituric acids range from pK 7.1 to 8.1.⁶ The acids can undergo a second ionization as well. The pK values are in the range of 11.7-12.7.⁷ It appeared reasonable, therefore, to assume that a dialkali metal salt of a 5,5disubstituted barbituric acid could be prepared. The dialkali metal salt of a 5,5-disubstituted barbituric acid, in turn, could be converted (without isolating the salt) into 1,3-bis(alkoxymethyl)-5,5-disubstituted barbituric acids upon reaction with an alkyl chloromethyl ether. Indeed the disodium salt of phenobarbital, obtained from phenobarbital and 2 moles of NaH in DMF, could be converted in nearly quantitative yield into **2** by treating the disodium salt *in situ* with 2 moles of ClCH₂-OCH₃, as shown:

⁽¹⁾ Kendall Co., Cambridge, Mass.

^{(3) (}a) B. Wyke, "Principles of General Neurology," Elsevier, Amsterdam, 1969, p 288; (b) D. M. Woodbury "Basic Mechanisms of the Epilepies," H. H. Jasper, A. A. Ward, and A. Pope, Ed., Little Brown and Co., Boston, Mass., 1969, pp 647-688.

⁽⁴⁾ R. P. Schmidt and B. J. Wilder, "Epilepsy," F. A. Davis, Philadelphia, Pa., 1968, p 148.

⁽⁵⁾ L. Meyler, Ed., "Side Effects of Drugs," Volume V, Excerpta Medica Foundation, Amsterdam, 1966, pp 78-82.

⁽⁶⁾ W. J. Doran, Med. Chem., 4, 8 (1959).

⁽⁷⁾ T. C. Butler, J. M. Ruth, and G. F. Tucker, J. Amer. Chem. Soc., 77, 1488 (1955).

LD 50.

mg/kg

>500 <1000


>500 > 500>375 < 500

>500

>1000

470 (376-588)

TABLE I PHARMACOLOGICAL ACTIVITY OF 1,3-BIS(ALKOXYMETHYL)-5,5-DISUBSTITUTED BARBITURIC ACIDS




Met ED_{50}

mg/kg

6.2(4.6-8.4)

>200 ~ 100

			MES,
			ED_{50}
\mathbf{R}_1	\mathbf{R}_2	\mathbf{R}_3	mg/kg
CH_3	C_2H_5	C_6H_5	13.5 (8-22)
$C_6H_5CH_2$	C_2H_5	C_6H_5	~ 25
$n-C_4H_9$	C_2H_5	C_6H_5	>50 < 100
C_2H_5	C_2H_5	C_6H_5	>12.5 < 25
$n-{ m C_{12}H_{25}}$	$C_{2}H_{3}$	C_6H_5	~ 50
CH_3	C_2H_5	C_2H_5	~ 50
n-C ₁₂ H ₂₅	C_2H_5	C_2H_5	
CH_3	Allyl	2-Pentyl	$<\!200$
$C_6H_5CH_2$	Allyl	2-Pentyl	>200



Pharmacological Studies. Maximal Electroshock Seizures (MES) and Time of Peak Effect in the Mouse. -The procedure was the same as that of Swinyard, et al.,⁸ except that (1) Charles River mice were used and (2) a current of 60 mA was employed for corneal stimulation. The time of peak anticonvulsant activity (MES) was determined according to Swinyard, et al.⁸

Antipentylenetetrazole Activity (Met).-The procedure of Swinyard, et al.,⁸ was followed, except for using Charles River mice, and a dosage of 106 mg/kg of pentylenetetrazole.


Acute Toxicity.-The compound was suspended or dissolved in 10% aq acacia and administered orally to adult male albino mice at 1-5 dosage levels. Deaths were recorded daily for 1 week.

Median effective and lethal dose $(ED_{50} \text{ and } LD_{50})$ was determined according to Litchfield and Wilcoxon.⁹

Hypnotic Activity.—The pattern of toxicity in mice and rats disclosed progressive depression of the CNS; death resulting from respiratory paralysis. Sleep, however, did not appear except at lethal doses.

The results of these studies have been summarized in Tables I and II. The anticonvulsant activity of the aliphatic alkoxymethylbarbiturates decreased as the size of the alkoxy group increased (see Table III). In the methoxy-, ethoxy-, n-butoxy-, and n-dodecyloxymethyl series the methoxymethyl derivatives were the most potent anticonvulsants. Alkoxymethyl-substituted derivatives, where the alkoxy substituent is branched aliphatic or alicyclic, offered no advantage over the methoxymethyl derivative.

In the 5,5-diphenylhydantoin series (see Table IV) activity against maximal electroshock seizures decreased as the size of the alkoxy group increased. Thus, while the methoxymethyl derivative was weakly active against pentylenetetrazole, both the n-butoxymethyl



Peak time,

hr

 $\mathbf{2}$

1

1.5 $\mathbf{2}$

1

and benzyloxymethyl derivatives displayed good activity against chemoshock.

Experimental Section

Microanalyses were within $\pm 0.3\%$ of the theoretical values as performed by Galbraith Laboratories, Knoxville, Tenn. Melting points were obtained on a Fisher-Johns hot stage and are corrected. Ir spectra were recorded on a Perkin-Elmer 337 grating infrared spectrophotometer. Nmr spectra were run on a Varian Associates A60A spectrometer in (CD₃)₂SO using Me₄Si as internal reference. All ir and nmr spectra were obtained as expected. Mass spectra were determined on a Hitachi RMU-6D double focusing spectrometer at 70 eV.

Chromatographic separations were obtained using silica gel, Davison Type 950, 60-200 mesh. Evapns were carried out on a Büchi Rotavapor apparatus. Merck HF-254 + 366 silica gel, according to Stahl, was used for tlc development with PhH-EtOAc mixts.

1.3-Bis(alkoxymethyl)-5,5-disubstituted Barbituric Acids.-The following examples illustrate the procedures used in the preparation of these compds, shown in Table III.


Procedure A.—To a suspension of 1 (25.4 g, 0.1 mole) in DMF (100 ml) was added a 2.2 equiv wt of $ClCH_2OCH_3$. The 0.1 mole) in reaction mixt was stirred at 25° for 20 hr, then poured into ice-H₂O (200 ml). The product was removed by filtrn, washed with H₂O, and crystd from EtOH to yield 14.8 g of 2, mp 116-


Procedure B.-Sodium barbital (4.1 g, 0.02 mole) was suspended in DMF (20 ml). ClCH₂OCH₃ (2.2 equiv wt) was added over a period of 15 min. The reaction mixt was stirred for 4 hr and poured into ice-H₂O (100 ml), and the product was extd into EtOAc. The dried (Na_2SO_4) EtOAc soln was evapd and the product was purified by column chromatography on silica gel. Elution with a C₆H₆-EtOAc mixt (9:1 by vol) yielded pure 1,3-bis-(methoxymethyl)-5,5-diethylbarbituric acid (2.2 g), an oil.

Procedure C.-Phenobarbital (23.2 g, 0.1 mole) was dissolved in DMF (250 ml). To the soln was added KO-tert-Bu (11.29 g)


⁽⁸⁾ E. A. Swinyard, W. C. Brown, and L. S. Goodman, J. Pharmacol. Exp. Ther., 106, 319 (1952).

⁽⁹⁾ J. T. Litchfield, Jr. and F. Wilcoxon, ibid., 96, 99 (1949).





^a This experiment was carried out at room temp. ^b All compds were analyzed for C, H, N.



and the mixt was warmed to 100° at which temp all solids had dissolved. The soln was cooled to 50°, and ClCH₂OCH₃ (8 g) was added, and the mixt was stirred for 1 hr. To the suspension another amt of KO-tert-Bu (11.29 g) was added and the mixt was heated to 50°. Another portion of ClCH₂OCH₃ (16 g) was added, the mixt was stirred for 1 hr and then pured into ice-H₂O, and the ppt was removed by filtrn and washed with H₂O. The crude product was crystd from EtOH to yield 20 g of 2, mp 116-118°.

Procedure D.—Phenobarbital (23.2 g, 0.1 mole) was dissolved in DMF (250 ml). To the cooled soln LiH (1.6 g, 0.2 mole) was added and the mixt was stirred for 30 min. $ClCH_2OCH_3$ (2.2 equiv wt) was added to the mixt over a period of 30 min. The reaction mixt was stirred for 1 hr, then poured into ice-H₂O (120 ml). The solid ppt was filtered, washed with H₂O, and crystd from EtOH. The yield of 2 was 29.4 g (92%), mp 116-118°. **Procedure E.**—Barbital (1.87 g, 0.01 mole) was dissolved in DMF (20 ml). To the soln was added LiH (176 mg, 0.022 mole), the mixt was stirred for 20 min, then *n*-dodecyl chloromethyl ether¹⁰ (5.1 g, 0.0218 mole) was added, and the reaction mixt was warmed to 100°, stirred for 30 min, allowed to cool to 25° overnight, and poured into ice-H₂O. The product was extd into EtOAc, the solvent evapd, and the crude product purified by column chromatography on silica gel. Elution with a C₆H₆-EtOAc mixt (8:2 by vol) provided pure 1,3-bis(*n*-dodecyloxymethyl)-5,5-diethylbarbituric acid (3.2 g).

3-Alkoxymethyl-5,5-diphenylhydantoin.—The following example illustrates the procedure used in the prepn of 3-alkoxymethyl-5,5-diphenylhydantoins. 5,5-Diphenylhydantoinsodium (27.5 g, 0.1 mole) was suspended in DMF (250 ml). To the suspension $\text{ClCH}_2\text{OCH}_3$ (8.8 g, 0.11 mole) was added over a period of 30 min. The reaction mixt was stirred at 25° overnight, then poured into H₂O (1000 ml). The solid ppt was removed by filtrn, washed with H₂O, and crystd from aq EtOH (50%) to yield pure 3-methoxymethyl-5,5-diphenylhydantoin, (20 g, 67%), mp 127-128°.

Acknowledgment.—We are indebted to Dr. L. G. Donaruma, Clarkson College of Technology, Potsdam, N. Y., and Dr. James E. Gearien, Department of Chemistry, College of Pharmacy, University of Illinois, Chicago, Ill., for their aid and counsel.

(10) All alkyl chloromethyl ethers were prepared according to A. J. Hill and De W. T. Keach, J. Amer. Chem. Soc., **48**, 257 (1926). Compare German Patent 578,568 (1931) and U. S. Patent 2,012,073 (1931).